Payment overview · 2025
General Payments
$338.32
20 reported records · 13 companies
Healthcare provider profile · identity verified
Todd W. Stuckey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · YORK, NE · NPI 1154377810
Verified facts
What the public records show
CMS Open Payments records show Todd W. Stuckey, M.D. received $338.32 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.08 | 16.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.56 | 13.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.43 | 9.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.09 | 9.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.24 | 9.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.47 | 7.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.86 | 5.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.89 | 5.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.33 | 5.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.61 | 4.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.96 | 4.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.21 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.59 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $338.32 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $50.13 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.56 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $36.45 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 70 |
| Furosemide | Furosemide | 258 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 72 |
| Omeprazole | Omeprazole | 224 | 61 |
| Enalapril Maleate | Enalapril Maleate | 197 | 41 |
| Losartan Potassium | Losartan Potassium | 177 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 34 |
| Lisinopril | Lisinopril | 159 | 42 |
| Metformin Hcl Er | Metformin Hcl | 156 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 36 |
| Montelukast Sodium | Montelukast Sodium | 152 | 33 |
| Alendronate Sodium | Alendronate Sodium | 144 | 30 |
| Farxiga | Dapagliflozin Propanediol | 136 | 29 |
| Glipizide Er | Glipizide | 136 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 35 |
| Nebivolol Hcl | Nebivolol Hcl | 123 | 24 |
| Eliquis | Apixaban | 114 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 26 |
| Donepezil Hcl | Donepezil Hcl | 104 | 19 |
| Spironolactone | Spironolactone | 96 | 22 |
| Carvedilol | Carvedilol | 89 | 24 |
| Potassium Chloride | Potassium Chloride | 86 | 21 |
| Memantine Hcl | Memantine Hcl | 84 | 14 |
| Alprazolam | Alprazolam | 81 | 21 |
| Gabapentin | Gabapentin | 80 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 18 |
| Meloxicam | Meloxicam | 71 | 32 |
| Tramadol Hcl | Tramadol Hcl | 70 | 17 |
| Sertraline Hcl | Sertraline Hcl | 69 | 15 |
| Allopurinol | Allopurinol | 66 | 18 |
| Xarelto | Rivaroxaban | 65 | 18 |
| Simvastatin | Simvastatin | 62 | 14 |
| Jardiance | Empagliflozin | 61 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 19 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 58 | 57 |
| Trazodone Hcl | Trazodone Hcl | 58 | 18 |
| Famotidine | Famotidine | 53 | suppressed |
| Ezetimibe | Ezetimibe | 52 | 13 |
| Metformin Hcl | Metformin Hcl | 52 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Azithromycin | Azithromycin | 43 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 12 |
| Dutasteride | Dutasteride | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 28 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 30 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Fetzima | Levomilnacipran Hcl | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 21 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $338.32 · 20 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, Kerendia, NEXLETOL, QULIPTA, REXULTI, UBRELVY, Veozah, Wegovy, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error